Press Releases

Home / Investors

MyDx Reports Strong Third Quarter 2016 Financial Results

New Licensing Model to Drive Rapid Earnings Growth and 
Rebuild Shareholder Value in 2017

Third Quarter Highlights:

  • Changes Business Model with Initial $2.5 Million Licensing Deal 
  • Company Reduces Operating Cash Burn by 83%
  • Launches AquaDxTM and OrganaDxTM Sensors
  • New MyDx Smart Phone App Tops Apple iOS App Store Charts
  • Anticipates Reaching Positive Cash Flow in Current Quarter
  • Expects to Enter 2017 with a Strengthened Balance, Poised for Profitability

LA JOLLA, Calif., Nov. 23, 2016 (GLOBE NEWSWIRE) --  MyDx, Inc. (OTCQB:MYDX), a rapidly growing science and technology company that has developed MyDx®, the first multi-use handheld chemical analyzer for consumers, today announced its financial results for the third quarter ended September 30, 2016 and provided guidance that -- fueled in part by its new licensing model -- it expects to reach positive cash flow in the fourth quarter ending December 31, 2016 and achieve profitability in early 2017.

Strong, Third Quarter Operating Results
For the three months ended September 30, 2016 and 2015, the Company had net revenues of $134,240 and $219,180, respectively. The comparable decline in net revenues, year over year, reflects the revenues from CannaDx shipments in 2015 that were a cumulative buildup of nearly one year of pre-sales.  For the three months ended September 30, 2016 and 2015, gross profit as a percentage of net revenues held steady at a healthy 40.2% and 40.8%, respectively.

For the three months ended September 30, 2016, the Company incurred operating expenses in the amount of $1,976,382 compared to $1,447,564 for the three months ended September 30, 2015. In the quarter ended September 30, 2016, the increase in expenses were a direct result of new investments made to create and launch a new global licensing model, with an initial emphasis across the greater China region.  The Company’s licensing deal is expected to generate a minimum of $2.5 million in Earnings over the next 5 years.

On an operating basis, for the nine months ended September 30, 2016, MyDx reported net cash used in operating activities declined approximately 83% to ($698,547) compared with ($4,104,595) in the nine months ended September 30, 2015. For the quarter ended September 30, 2016, MyDx posted a net loss of ($2.87 million) or ($0.08) per share compared with a net loss of ($1.36 million) or ($0.06) per share in the year earlier quarter.

Commenting on the Company’s achievements, Daniel R. Yazbeck, MyDx Chairman and CEO, said, “Over the last nine months, we streamlined our operations across the board, reducing our operating cash burn by 83% year over year, which solidifies our path towards becoming cashflow positive by the end of the fourth quarter and profitable in 2017. 

“During the third quarter, while completing the development, branding and launch of the AquaDx and OrganaDx product lines, we have been working diligently to create, negotiate and close a landmark Asian licensing distribution deal,” he added. “We are pleased to report successfully closing a 5 year $2.5 million high-margin transaction with our first licensing partner in China who will market and distribute the OrganaDx, AquaDx, and AeroDx product lines in that region.”

Q316 Progress: Triples Product Lines and Reaches Top of the iOS Charts

Driven by widespread liberalization of marijuana laws at the state level in the Nov. 8 US Election and a successful test marketing campaign, on November 15, the Company announced its CannaDxTM iOS smartphone app had catapulted to the top of the Apple iOS App Store Charts. This is a major accomplishment following its June 1, launch of its new, feature-rich CannaDxTM smart phone App for both iOS and Android platforms.

In addition to CannaDxTM Sensor launched in late 2015, in recent weeks, the Company has tripled its number of product lines launching two new Sensor Chips for its Analyzer that address major, global mass markets:

“We believe 2017 will be a watershed year for MyDx and its shareholders as we expand on our new products launches and licensing model. We extend our sincere thanks to our partners, customers, shareholders and industry advocates for their continued support of our mission,” Mr. Yazbeck concluded.

About MyDx, Inc.
MyDx, Inc. (OTCQB:MYDX) is a chemical detection and sensor technology company based in San Diego, California whose mission is to help people Trust & Verify® what they put into their minds and bodies. The Company developed MyDx®, a patented, affordable portable analyzer that provides real-time chemical analysis and fits in the palm of the user’s hand. The multi-use MyDx analyzer leverages over a decade of established chemical detection technology to measure chemicals of interest. The Company owns a substantial and growing intellectual property portfolio of patents covering its technology. The MyDx CannaDxTM, AquaDxTM and OrganaDxTM sensors are now commercialized, and the AeroDxTM application is next in line. All Sensors will be compatible with a MyDx App that empowers consumers to test the chemical composition of what they eat, drink and inhale. For more information, please visit www.cdxlife.com.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance and developments, as well as other statements relating to future operations and results. Any statements in this press release that are not statements of historical fact may be considered to be forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. These forward-looking statements by their nature are estimates of future results only and involve substantial risks and uncertainties, including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, our ability to complete our product testing and launch our product commercially, the acceptance of our product in the marketplace, the uncertainty of the laws and regulations relating to cannabis, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed from time to time in our reports filed with the Securities and Exchange Commission, available at http://ir.cdxlife.com/all-sec-filings or www.sec.gov.

MyDx, INC.  
CONDENSED CONSOLIDATED BALANCE SHEETS  
(unaudited)  
   
    September 30,     December 31,  
ASSETS   2016     2015  
             
Current assets:            
Cash   $ 183,752     $ 143,680  
Accounts receivable     40,397       10,702  
Inventory     341,522       451,973  
Prepaid expenses and other current assets     34,264       51,978  
Total current assets     599,935       658,333  
Property and equipment, net     160,516       233,064  
Other assets     87,828       104,365  
Total assets   $ 848,279     $ 995,762  
                 
LIABILITIES AND STOCKHOLDERS' DEFICIT                
                 
Current liabilities:                
Asset based loans   $ 223,497     $ -  
Accounts payable     843,662       619,528  
Customer deposits     56,312       9,467  
Accrued liabilities     1,472,617       281,761  
Current portion of leases payable     2,915       2,773  
Due to related party     1,075       1,075  
Derivative liability     111,048       -  
Convertible notes payable, current     309,649       50,574  
Total current liabilities     3,020,775       965,178  
Long-term liabilities                
Note payable - Related Party     200,000       175,000  
Convertible notes payable     -       200,274  
Other long-term obligations     508       2,721  
Total liabilities     3,221,283       1,343,173  
                 
Commitments and contingencies (Note 11)                
                 
Stockholders' deficit:                
Preferred stock, $0.001 par value, 10,000,000 authorized; zero shares issued as of September 30, 2016 and December 31, 2015, respectively.     -       -  
Common stock, $0.001 par value, 10,000,000,000 shares authorized; 114,620,112 and 22,081,928 shares issued and outstanding as of September 30, 2016 and December 31, 2015, respectively     114,620       22,081  
Additional paid-in capital     11,757,927       9,528,072  
Accumulated deficit     (14,245,551 )     (9,897,564 )
Total stockholders' deficit     (2,373,004 )     (347,411 )
Total liabilities and stockholders' deficit   $ 848,279     $ 995,762  
                 

  

MyDx, INC.  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS  
(unaudited)  
   
    for the three months
ended
September 30,
    for the nine months
ended
September 30,
 
      2016
      2015
      2016
      2015
 
Net Revenues   $ 134,240     $ 219,180     $ 574,880     $ 219,180  
Cost of goods sold     79,434       131,173       285,123       131,173  
Gross profit     54,806       88,007       289,757       88,007  
Operating Expenses                                
Research and development     111,315       364,370       352,407       1,717,784  
Sales and marketing     1,588,884       203,091       1,792,496       875,744  
General and administrative     276,183       880,103       1,416,440       2,779,156  
Total operating expenses     1,976,382       1,447,564       (3,561,343 )     5,372,684  
Loss from operations     (1,921,576 )     (1,359,557 )     (3,271,586 )     (5,284,677 )
Interest expense, net     807,622       1,051       863,001       442,811  
Change in fair value of derivative liability     (198,338 )     -       (198,338 )     -  
Loss on settlement of debt     335,952       -       409,887       -  
Loss before provision for income taxes     (2,866,812 )     (1,360,608 )     (4,346,136 )     (5,727,488 )
Provision for income taxes     -       575       1,850       1,375  
Net loss   $ (2,866,812 )   $ (1,361,183 )   $ (4,347,986 )   $ (5,728,863 )
                                 
Basic and diluted loss per share   $ (0.08 )   $ (0.06 )   $ (0.15 )   $ (0.35 )
Weighted average shares used in computing net loss per share                                
Basic and diluted     34,235,772       21,845,932       29,750,062       16,601,476  
                                 

 

Investor Contact:
Phillip Sugarman, Vice President
Investor Relations Partners
Phone: 818-280-6800
psugarman@irpartnersinc.com

Primary Logo

Source: MyDx, Inc.